Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for the treatment of severe genetic diseases.
stoketherapeutics.com.
Location: United States, Massachusetts, Bedford
Total raised: $130M
Investors 3
Funding Rounds 2
| Date | Series | Amount | Investors |
| 23.10.2018 | Series B | $90M | - |
| 04.01.2018 | Series A | $40M | Apple Tree... |
Mentions in press and media 23
| Date | Title | Description | Source |
| 07.04.2022 | Stoke Therapeutics to Present at The Association for Researc... | New preclinical data support the ongoing preclinical development of STK-002 for the treatment of aut... | appletreep... |
| 07.04.2022 | Stoke Therapeutics to Present at The Association for Researc... | New preclinical data support the ongoing preclinical development of STK-002 for the treatment of aut... | appletreep... |
| 10.03.2022 | Stoke Therapeutics Reports Fourth Quarter and Full Year 2021... | – Enrollment and dosing ongoing in the Phase 1/2a MONARCH and ADMIRAL studies of STK-001 in children... | appletreep... |
| 10.03.2022 | Stoke Therapeutics Reports Fourth Quarter and Full Year 2021... | – Enrollment and dosing ongoing in the Phase 1/2a MONARCH and ADMIRAL studies of STK-001 in children... | appletreep... |
| 03.12.2021 | Stoke Therapeutics Presents Data from the Phase 1/2a MONARCH... | Single doses of STK-001 up to 30mg and multiple doses of 20mg were well tolerated with no safety con... | appletreep... |
| 03.12.2021 | Stoke Therapeutics Presents Data from the Phase 1/2a MONARCH... | Single doses of STK-001 up to 30mg and multiple doses of 20mg were well tolerated with no safety con... | appletreep... |
| 08.11.2021 | Stoke Therapeutics Reports Third Quarter Financial Results a... | Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates - Company ... | marketscre... |
| 21.09.2021 | Stoke Therapeutics Announces Positive Interim Safety, PK and... | – Results show that single doses of STK-001 up to 30mg and multiple doses of 20mg were well-tolerate... | appletreep... |
| 30.03.2021 | Stoke Therapeutics Announces MHRA Authorization to Initiate ... | New ADMIRAL study complements ongoing U.S. studies and marks first step in global expansion of clini... | appletreep... |
| 30.03.2021 | Stoke Therapeutics Announces MHRA Authorization to Initiate ... | New ADMIRAL study complements ongoing U.S. studies and marks first step in global expansion of clini... | appletreep... |
Show more